Seminars in Nephrology
Volume 24, Issue 5 , Pages 437-440, September 2004

New cellular and molecular approaches for the treatment of cardiac disease

Based on a plenary lecture presented at the Third International Congress on Uremia Research, Taormina, Sicily, September, 2003.

  • Laurence Kedes

      Affiliations

    • Institute for Genetic Medicine, Keck School of Medicine, Los Angeles, CA, USA
    • Corresponding Author InformationAddress reprint requests to Laurence Kedes, MD, Institute for Genetic Medicine, Keck School of Medicine, 2250 Alcazar St, Building CSC 240, Los Angeles, CA 90033
  • ,
  • Robert Kloner

      Affiliations

    • The Heart Institute, Good Samaritan Hospital, Los Angeles, CA, USA
  • ,
  • Kimi Kong

      Affiliations

    • Institute for Genetic Medicine, Keck School of Medicine, Los Angeles, CA, USA
  • ,
  • Coralie Poizat

      Affiliations

    • Institute for Genetic Medicine, Keck School of Medicine, Los Angeles, CA, USA
  • ,
  • Boris Simkhovich

      Affiliations

    • The Heart Institute, Good Samaritan Hospital, Los Angeles, CA, USA
  • ,
  • Tatsuya Iso

      Affiliations

    • Institute for Genetic Medicine, Keck School of Medicine, Los Angeles, CA, USA
  • ,
  • Yasuo Hamamori

      Affiliations

    • The Center for Cardiovascular Development, Department of Medicine, Baylor College of Medicine, Houston, TX, USA

Similar to the kidney in uremia, end-stage cardiac failure is an outcome common to many disparate disease processes including hypertension, various inflammatory pathologies, as well as ischemic loss of tissue. In regard to the heart, cellular and molecular mechanisms responsible for heart failure have been investigated with renewed intensity over the past several years with newer techniques of molecular genetics, genomic analysis, and cell biology. Although this article reviews some recent advances made in our understanding of molecular and cellular events in the heart leading to heart failure and explores possible new targets for therapeutics, the main point is to stress the importance of investigative interactions between organ physiologists and molecular and cellular biologists. These interactions between organ physiologists and molecular geneticists is stressed and supported as a mechanism for rapid advancement for both understanding the underlying pathophysiology of human disease and the development of therapeutic strategies.

Keywords:  cardiac , heart , gene therapy , notch , transcription , vascularization , tropomodulin , myofilament

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by grants from the National Institutes of Health.

PII: S0270-9295(04)00093-2

doi:10.1016/j.semnephrol.2004.06.010

Seminars in Nephrology
Volume 24, Issue 5 , Pages 437-440, September 2004